ONGLYZA (Saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes Bristol-Myers Squibb Company and AstraZeneca announced that their marketing authorization application for ONGLYZA received a positive opinion from the Committee for Medicinal Products for Human Use for the treatment of type 2 diabetes in adults as add-on therapy with metformin, a thiazolidinedione or a sulphonylurea. [more...]
